RVMD Stock: Price, Earnings History and SEC Filings
Revolution Medicines, Inc. (RVMD) last traded at $191.31, up 0.55% on the latest session and down 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.34 against an analyst estimate of $-1.93, a miss of 21.2%.
$191.31 +0.55%
1 month-6.80%
52-week high$224.31
52-week low$56.66
Volume1.10M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RVMD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-2.34 | $-1.93 | -21.24% |
| Mar 2026 | May 6, 2026 | $-2.29 | $-1.83 | -25.14% |
| Dec 2025 | Feb 25, 2026 | $-1.86 | $-1.56 | -19.23% |
| Sep 2025 | Nov 5, 2025 | $-1.61 | $-1.39 | -15.83% |
RVMD beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RVMD
SEC filing data is not available right now. You can search for RVMD on SEC EDGAR.
RVMD news
- Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"Oct 30, 2026 · finance.yahoo.com
- Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct CompetitionOct 29, 2026 · stocktwits.com
- NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”Oct 29, 2026 · tikr.com
- Could Revolution Medicines Be a Millionaire-Maker Stock?Oct 29, 2026 · fool.com
- Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?Oct 27, 2026 · fool.com
- Revolution Medicines to Participate in November 2026 Investor ConferencesOct 27, 2026 · finance.yahoo.com
- What 3 multibillion dollar biotechs still have to proveOct 27, 2026 · pharmavoice.com
- Cantargia Appoints Dr. Monic Stuart as Chief Medical OfficerOct 26, 2026 · finance.yahoo.com
About Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) is a US-listed public company on Nasdaq.